SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by da Rocha Dias, S. Articles by Rudd, C. E. Search for Related Content PubMed PubMed Citation Articles by da Rocha Dias, S. Articles by Rudd, C. E. Related Collections Immunobiology Apoptosis Signal Transduction Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 February 2001, Vol. 97, No. 4, pp. 1134-1137 BRIEF REPORT CTLA-4 blockade of antigen-induced cell death Silvy da Rocha Dias and Christopher E. Rudd From the Division of Tumor Immunology, Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston, MA.     Abstract Top Abstract Introduction Study design Results and discussion References While cytotoxic T lymphocyte antigen-4 (CTLA-4) negatively regulates T-cell receptor (TCR)-driven interleukin (IL)-2 production and proliferation, little is known regarding whether the coreceptor has the capacity to inhibit other events, such as Fas ligand (FasL) expression and antigen-induced cell death (AICD). In this study, it is shown that CTLA-4 expressed in a T-cell hybridoma can elicit a potent block of FasL expression and AICD. Inhibition occurred independently of CTLA-4 blockage of IL-2 production and was partially reversed by a single mutation in the cytoplasmic YVKM motif. These findings indicate that CTLA-4 can block TCR signaling prior to bifurcation of signals leading to IL-2 production and apoptosis. (Blood. 2001;97:1134-1137) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Study design Results and discussion References Cytotoxic T lymphocyte antigen-4 (CTLA-4) negatively regulates T-cell activation initiated by ligation of T-cell receptor (TCR)/CD3 and CD28.1-3 Blocking with soluble anti-CTLA-4 Fab fragments can augment T-cell responses,4,5 while co-cross-linking of CTLA-4 with either TCR or TCR × CD28 potently inhibits proliferation and interleukin (IL)-2 production.6-8 Consistent with this, CTLA-4/ mice show extensive lymphadenopathy with T-cell infiltration of various tissues.9-13 This event requires CD28 since CTLA-4Ig blockage of CD28 binding to CD80/86 reverses the phenotype.11 Isolated CTLA-4/ T-cells also exhibit a greatly enhanced response to antigen,14-16 leading to the notion that the lowering of the signaling threshold to self-antigen and/or weakly antigenic foreign antigen is responsible for the lymphadenopathy. In this context, TCR transgenic mice on a Rag/ × CTLA-4/ background fail to develop disease.15,16 CTLA-4 has also been linked to anergy induction,17,18 while its absence enhances the development of TH2 cells.12 Despite its immunologic importance, the molecular basis for CTLA-4 function has yet to be established. Multiple intracellular proteins, including phosphatidylinositol 3-kinase (PI3-K),19,20 the tyrosine phosphatase SHP-2,21,22 as well as the clathrin-associated adaptor protein complexes AP-223-26 and AP-127 interact with the cytoplasmic domain. PI3-K, AP-1 and AP-2 bind directly to the GVYVKM motif, while the SHP-2 association appears to be indirect, possibly mediated through another protein such as PI3-K.28 PI3-K binds a tyrosyl-phosphorylated version of the motif,19 while AP-1/AP-2 complexes bind to an extended version of the nonphosphorylated sequence that includes additional N-terminal residues.23-26 The AP-2 tetramer regulates trafficking and endocytosis of the coreceptor from the cell surface.24,26 AP-1 acts to ensure steady-state levels of intracellular CTLA-4 by shuttling the receptor to lysosomes for degradation.27 Further downstream, CTLA-4 engagement has been reported to block extracellular signal-regulated kinase and Jun NH2-terminal kinase activity29 and the induction of IL-2 transcription.30-32 TCR/CD3 ligation induces antigen-induced cell death (AICD) as mediated by Fas (CD95/APO-1) and Fas ligand (CD95L) interactions and the activation of caspases, a process that ensures the elimination of self-reactive thymocytes and peripheral blood lymphocytes.33-36 Although AICD operates in CTLA-4/ T cells,14 little is known regarding whether CTLA-4 has the capacity to block TCR-mediated signals leading to AICD. In this regard, T-cell hybridomas have served as a model for the study of AICD33,34; in particular, the hybridoma DC27.10 has been previously studied for the role of costimulation in the induction of apoptosis.37 In this report, we demonstrate that CTLA-4 can block AICD in transfectants of the murine hybridoma DC27.10 via inhibition of Fas ligand (FasL) surface expression. These findings support a model in which CTLA-4 interferes with an early TCR-signaling event linked to both IL-2 production and FasL expression.     Study design Top Abstract Introduction Study design Results and discussion References Cells, reagents, and antibodies Murine T-cell hybridoma DC27.10 (gift from Dr R. Zamoyska, Medical Research Council, London, United Kingdom) was cultured in RPMI-1640 containing fetal bovine serum 5% (vol/vol) (Sigma, St Louis, MO), L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL) (Life Technologies, Grand Island, NY) at 37°C, and 5% CO2. DC27.10 transfectants carrying different transfected forms of human CTLA-4 (wild-type human CTLA-4, Y201-2F) were generated as described.38 Hamster anti-murine CD3 (145-2C11) was purchased from American Type Culture Collection (Manassas, VA), mouse anti-human CTLA-4 (BNI3.1) was purchased from Immunotech (Marseilles, France). Mouse immunoglobulin G2a (specific for 2,4,6-trinitrophenol [TNP]), hamster anti-mouse CD28 (37.10) purified rat anti-mouse IL-2 (JES6-1A12), biotinylated rat anti-mouse IL-2 (JES6-5H4), and biotinylated anti-FasL were purchased from Pharmingen (San Diego, CA). Avidin-peroxidase was purchased from Sigma. ABTS tablets and recombinant mouse IL-2 were purchased from Boehringer Mannheim (Indianapolis, IN). Mouse anti-hamster was purchased from Sigma. Phycoerythrin-labeled streptavidin was a gift from the laboratory of Dr Lee Nadler, Dana-Farber Cancer Institute (Boston, MA). Stimulation assay For all experiments, stimulation of T-cell hybridoma was performed by means of antibodies bound to plates. The antibodies were added at their designated concentration in a 96-well microtiter plate and left to adsorb overnight at 4°C. The wells were washed twice with complete media, followed by the addition of cells at a density of 1.5 × 105 cells per well and incubation for 24 hours at 37°C. The cells were then harvested and analyzed for apoptosis. The supernatant was frozen for later measurements of IL-2 by enzyme-linked immunosorbent assay (ELISA) (Pharmingen). Apoptosis measurements The samples were fixed with propidium iodide (PI) staining buffer (sodium citrate 0.1%, sodium dodecyl sulfate 1%, 50 µg/mL PI) overnight at 4°C. Apoptosis was analyzed on an Epics XL flow cytometry system (Coulter, Hialeah, FL) by gating on the subdiploid population below the G1 peak.     Results and discussion Top Abstract Introduction Study design Results and discussion References Stable transfectants of the T-cell hybridoma DC27.10 were initially generated that express either wild-type human CTLA-4 (CTLA-4 WT), or a mutant form with a substituted cytoplasmic tyrosine at position 201 in the YVKM motif (Y201-F).27 Both CTLA-4 WT and Y201-F express the coreceptor at moderate levels with stable expression of TCR/CD3 and CD28 (Figure 1A). To assess whether CTLA-4 could influence the ability of the TCR/CD3 to induce apoptosis, anti-CD3 was immobilized on plates at a concentration of 0.5 µg/mL in the presence or absence of anti-CTLA-4 at a concentration of 10 µg/mL. Cell death was assessed 24 hours after stimulation by examining the DNA content by PI staining as described in "Study design." The results were confirmed by DNA laddering techniques (data not shown). Anti-CD3 induced AICD in transfected cells in the range of 50% to 65% as observed in 7 experiments (data not shown).33,34 Results were expressed as values relative to the anti-CD3 control. Coligation with anti-CTLA-4 caused a 60% reduction in the percentage of cells undergoing apoptosis in cells transfected with CTLA-4 WT (Figure 1B). In 7 experiments, anti-CTLA-4 blocked AICD within a range of 60% to 80%. No effect of anti-CTLA-4 was evident in vector-transfected control cells (Figure 1B). The efficacy of the AICD blocking was proportional to the concentration of anti-CTLA-4 in the range of 2 to 10 µg/mL (Figure 1C). Inhibition by CTLA-4 was also observed when anti-CD28 was coligated with anti-CD3 (Figure 1D). These findings indicate that coligation of CTLA-4 can attenuate anti-CD3-induced AICD. View larger version (41K): [in this window] [in a new window]   Figure 1. CTLA-4 inhibition of AICD in T-cell hybridoma transfected with human CTLA-4. (A) Fluorescent activated cell sorter (FACS) profile of TCR/CD3, human CTLA-4, and murine CD28 (mCD28) surface expression on transfectants. DC27.10 cells were stably transfected with a vector (denoted Vector), human CTLA-4 (denoted CTLA-4 WT), and CTLA-4 mutant (denoted Y201-F). (B) CTLA-4 inhibits AICD in CTLA-4 transfectants. Cells were stimulated on a 96-well plate coated with anti-CD3 (145-2C11) at a concentration of 0.5 µg/mL and with anti-CTLA-4 (10 µg/mL). Anti-TNP control antibody was added to keep a final concentration of 10.5 µg/mL with anti-CD3 alone. AICD was determined by PI as described in "Study design."  indicates media; , CD3; and , CD3 + CTLA-4. (C) CTLA-4 inhibits AICD in a concentration-dependent manner. Anti-CD3 was used at a concentration of 0.5 µg/mL, while anti-CTLA-4 was used at concentrations of 2, 5, and 10 µg/mL. Anti-TNP control antibody was added to keep the final concentrations equivalent.  indicates vector; , CTLA-4 WT; and , Y201F. (D) CTLA-4 inhibits AICD induced by anti-CD3 in conjunction with anti-CD28. Anti-CD3 was used at 0.5 µg/mL; anti-CD28 at 5 µg/mL; and anti-CTLA-4 at 5 µg/mL. Anti-TNP control antibody was added to keep the final concentrations equivalent.  indicates media; , CD3; , CD3 + CD28; , CD3 + CD28 + CTLA-4. The cytoplasmic tail of CTLA-4 has a tyrosine-based motif YVKM that binds several intracellular signaling proteins.19-22 Mutation of the tyrosine within the YVKM sequence renders the motif unable to bind to these proteins. Disruption of the YVKM motif rendered CTLA-4 significantly less effective in blocking AICD (Figure 1B-C). A titration of anti-CTLA-4 showed that this partial blockage in Y201-F was observed only at the highest concentration of anti-CTLA-4 (Figure 1C). This partial inhibition was also observed with anti-CD3 × CD28 cross-linking (Figure 1D). These observations indicate that the optimal blockage of AICD by CTLA-4 is dependent on an intact YVKM motif. CTLA-4 inhibition of IL-2 production is a hallmark of the blockage effects on T-cell activation.6,7 Indeed, IL-2 production was inhibited by anti-CTLA-4 in a dose-dependent manner of 2 to 10 µg/ml of antibody on the CTLA-4 WT cells, albeit slightly less than observed for AICD (Figure 2A). To control for the possibility that the loss of IL-2 contributed to AICD, exogenous recombinant IL-2 was added in excess to cultures with anti-CD3 plus anti-CTLA-4 (Figure 2B). Under these conditions, IL-2 did not restore the induction of cell death, indicating that CTLA-4 blockage of AICD was not due to its blockage of IL-2. View larger version (39K): [in this window] [in a new window]   Figure 2. CTLA-4 inhibition of AICD independent of a CTLA-4 effect on IL-2 production. (A) CTLA-4 inhibits AICD and IL-2 production in CTLA-4 transfectants. Cells were stimulated with anti-CD3 at a concentration of 0.5 µg/mL and a range of anti-CTLA-4 concentrations from 2 to 10 µg/mL. Supernatants were collected 24 hours after stimulation, and IL-2 levels were determined by ELISA. Anti-TNP control antibody was added to keep the final concentrations equivalent.  indicates IL-2 production; , relative apoptosis. (B) Addition of exogenous IL-2 does not reverse anti-CTLA-4 blockage of AICD. Cells were stimulated with 0.5 µg/mL of anti-CD3 and 10 µg/mL of anti-CTLA-4 with or without recombinant mouse IL-2 (20 U/mL).  indicates media; , CD3; , CD3 + CTLA-4; , CD3 + rIL-2; , CD3 + CTLA-4 + rIL-2. AICD in T-cell hybridomas is mediated by the expression of Fas (CD95/APO-1), the expression of FasL (CD95L), and the activation of caspases.33,34 To investigate whether CTLA-4 blocks AICD by means of an inhibitory effect on FasL expression, cells were incubated with anti-CD3 in the presence or absence of anti-CTLA-4 followed by staining for FasL surface expression. Under these conditions, anti-CTLA-4 coligation caused a 4- to 5-fold reduction in the level of FasL expression (Figure 3A). This level of inhibition correlated well with the overall reduction of AICD (Figure 1A-D). Fas expression was also reduced, but to a lesser extent and less reproducibly (data not shown). The blockage of FasL expression was observed reproducibly in 4 experiments. To confirm that the AICD in our hybridomas was mediated by Fas/FasL binding, blocking anti-FasL antibodies were added to cultures and found to completely inhibit cell death (Figure 3B). CTLA-4 therefore impinges on TCR-induced apoptosis by blocking the expression of FasL. View larger version (15K): [in this window] [in a new window]   Figure 3. Engagement of CTLA-4 accompanying reduced FasL surface expression. (A) Anti-CTLA-4 reduced expression of FasL. Cells transfected with CTLA-4 WT were stimulated with the indicated antibodies bound to plates: anti-CTLA-4 (10 µg/mL), anti-TNP (10 µg/mL) control, and anti-CD3 (0.5 µg/mL). The cells were harvested after 6 hours, stained with biotinylated anti-FasL antibody followed by fluorescein isothiocyanate-labeled avidin. Subsequently, the cells were gated and analyzed by flow cytometry. A histogram of FasL staining on FL-1 is displayed. (B) Anti-FasL blocks anti-CD3-induced apoptosis in DC27.10 transfectants. CTLA-4 WT transfectants were stimulated with the indicated antibodies bound to plates: anti-CTLA-4 (10 µg/mL), anti-TNP (10 µg/mL) control, and anti-CD3 (0.5 µg/mL) with or without soluble blocking anti-FasL antibody (10 µg/mL). The cells were harvested 24 hours later and stained with PI. Apoptosis was measured as described in "Study design."  indicates control; , CD3; , CD3 + FasL. (C) Model of CTLA-4 blockage of IL-2 production and AICD. The coreceptor acts to dampen TCR/CD3 signaling at an early stage in T-cell activation prior to the bifurcation of signals leading to IL-2 production and FasL expression and AICD. Our findings provide the first evidence that CTLA-4 has the capacity to block TCR-signaling events that lead to FasL expression and AICD. Scheipers and Reiser44, however, have reported a role of CTLA-4 in the promotion of AICD. In their study, concanavalin A (ConA) is used as a stimulating agent instead of direct TCR cross-linking. It may be that stimulating with ConA and anti-CTLA-4 antibodies delivers different signals than using antibodies to directly cross-link the TCR with CTLA-4. Our study was not intended to address the physiological relevance of CTLA-4 on antigen-induced cell death, but rather to serve as a model to examine the point of blockage by CTLA-4 in the signaling cascade. With this perspective, our findings suggest that the coreceptor can block TCR signaling prior to the bifurcation of signals leading to FasL and IL-2 production (Figure 3C). Further CTLA-4 can block TCR signaling events that result in both positive (eg, IL-2 production) and negative outcomes (ie, apoptosis). Although the nature of signals that distinguish these events is unknown, p56lck and NF-AT have been reported to regulate both FasL and IL-2 expression.39 Other transcription factors, c-Myc, Egr 2, and Egr 3, have been implicated in FasL expression.40-42 In our system, the inhibitory effect of FasL expression and AICD must be an active process since it depends on the integrity of the cytoplasmic tail of the receptor (ie, YVKM motif). This contrasts with previous studies that demonstrated anti-CTLA-4 rescue of thymocytes from cell death by blockage of negative signaling.43 In this context, our cellular assay could be used as an assay to distinguish between antibodies that operate by actively generating negative signals vs those that simply block engagement of the receptor with CD80/CD86. Further analysis will also be needed to define which of these associated proteins regulates the blockage of AICD and IL-2 production.     Footnotes Submitted July 24, 2000; accepted October 5, 2000. Supported by National Institutes of Health grant 5P01AI35297, funding from the Fundação para a Ciência e Technologia Praxis XXI/BD/9652/1996, and a doctoral fellowship (S.d.R.D.) from the Fundação para a Ciência e Technologia Praxis XXI/BD/9652/1996, Portugal. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Christopher E. Rudd, Division of Tumor Immunology, Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: christopher_rudd{at}dfci.harvard.edu.     References Top Abstract Introduction Study design Results and discussion References 1. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994;15:321-331[CrossRef][Medline] [Order article via Infotrieve]. 2. Bluestone J. New perspectives of CD28-B7 mediated T cell costimulation. Immunity. 1995;2:555-559[CrossRef][Medline] [Order article via Infotrieve]. 3. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenutor. Immunity. 1997;7:445-450[Medline] [Order article via Infotrieve]. 4. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413[CrossRef][Medline] [Order article via Infotrieve]. 5. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465[Abstract/Free Full Text]. 6. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183:2533-2540[Abstract/Free Full Text]. 7. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996;183:2541-2550[Abstract/Free Full Text]. 8. Blair PJ, Riley JL, Levine BL, et al. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol. 1998;160:12-15[Abstract/Free Full Text]. 9. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985-988[Abstract/Free Full Text]. 10. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547[CrossRef][Medline] [Order article via Infotrieve]. 11. Tivol EA, Boyd SD, McKeon S, et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol. 1997;158:5091-5094[Abstract]. 12. Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol. 1999;162:5784-5791[Abstract/Free Full Text]. 13. Mandelbrot DA, McAdam AJ, Sharpe AH. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med. 1999;189:435-440[Abstract/Free Full Text]. 14. Waterhouse P, Bachmann MF, Penninger JM, Ohashi PS, Mak TW. Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice. Eur J Immunol. 1997;27:1887-1892[Medline] [Order article via Infotrieve]. 15. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A. 1999;96:8603-8608[Abstract/Free Full Text]. 16. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol. 1999;163:1128-1131[Abstract/Free Full Text]. 17. Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol. 1998;160:3855-3860[Abstract/Free Full Text]. 18. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997;6:411-417[CrossRef][Medline] [Order article via Infotrieve]. 19. Schneider H, Prasad KVS, Shoelson SE, Rudd CE. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med. 1995;181:351-355[Abstract/Free Full Text]. 20. Chambers CA, Allison JP. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. Eur J Immunol. 1996;26:3224-3229[Medline] [Order article via Infotrieve]. 21. Marengere LEM, Waterhouse P, Duncan GS, Mittrucker H-W, Feng G-S, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science. 1996;272:1170-1173[Abstract]. 22. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science. 1998;282:2263-2266[Abstract/Free Full Text]. 23. Bradshaw JD, Lu P, Leytze G, et al. Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation. Biochemistry. 1997;36:15975-15982[CrossRef][Medline] [Order article via Infotrieve]. 24. Shiratori T, Miyatake S, Ohno H, et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity. 1997;6:583-589[CrossRef][Medline] [Order article via Infotrieve]. 25. Zhang Y, Allison JP. Interaction of CTLA-4 with AP-50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A. 1997;94:9273-9278[Abstract/Free Full Text]. 26. Chuang E, Alegre M-L, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. J Immunol. 1997;159:144-151[Abstract]. 27. Schneider H, Martin M, Agarraberes FA, et al. Cytolytic T lymphocyte-associated antigen-4 and the TCRzeta/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J Immunol. 1999;163:1868-1879[Abstract/Free Full Text]. 28. Schneider H, Rudd CE. Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition. Biochem Biophys Res Commun. 2000;269:279-283[CrossRef][Medline] [Order article via Infotrieve]. 29. Calvo CR, Amsen D, Kruisbeek AM. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J Exp Med. 1997;186:1645-1653[Abstract/Free Full Text]. 30. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162:5813-5820[Abstract/Free Full Text]. 31. Fraser JH, Rincon M, McCoy KD, Le Gros G. CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells. Eur J Immunol. 1999;29:838-844[CrossRef][Medline] [Order article via Infotrieve]. 32. Olsson C, Riebeck K, Dohlsten M, Michaelsson E. CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. J Biol Chem. 1999;274:14400-14405[Abstract/Free Full Text]. 33. Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444-448[CrossRef][Medline] [Order article via Infotrieve]. 34. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 1995;373:441-444[CrossRef][Medline] [Order article via Infotrieve]. 35. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995;373:438-441[CrossRef][Medline] [Order article via Infotrieve]. 36. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 1998;280:243-248[Abstract/Free Full Text]. 37. Collette Y, Benziane A, Razanajaona D, Olive D. Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering: a role for Fas-FasL. Blood. 1998;92:1350-1363[Abstract/Free Full Text]. 38. Cai Y-C, Cefai D, Schneider H, Raab M, Nabavi N, Rudd CE. Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity. 1995;3:417-426[CrossRef][Medline] [Order article via Infotrieve]. 39. Oyaizu N, Than S, McCloskey TW, Pahwa S. Requirement of p56lck in T-cell receptor/CD3-mediated apoptosis and Fas-ligand induction in Jurkat cells. Biochem Biophys Res Commun. 1995;213:994-1001[CrossRef][Medline] [Order article via Infotrieve]. 40. Latinis KM, Norian LA, Eliason SL, Koretzky GA. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J Biol Chem. 1997;272:31427-31434[Abstract/Free Full Text]. 41. Brunner T, Kasibhatla S, Pinkoski MJ, et al. Expression of Fas ligand in activated T cells is regulated by c-Myc. J Biol Chem. 2000;275:9767-9772[Abstract/Free Full Text]. 42. Rengarajan J, Mittelstadt PR, Mages HW, et al. Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity. 2000;12:293-300[CrossRef][Medline] [Order article via Infotrieve]. 43. Cilio CM, Daws MR, Malashicheva A, Sentman CL, Holmberg D. Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. J Exp Med. 1998;188:1239-1246[Abstract/Free Full Text]. 44. Scheipers P, Reiser H. Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 cross-linking. Proc Natl Acad Sci U S A. 1998;95:10083-10088[Abstract/Free Full Text]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Mukherjee, A. Ahmed, S. Malu, and D. Nandi Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2 J. Leukoc. Biol., July 1, 2006; 80(1): 66 - 74. [Abstract] [Full Text] [PDF] D. Homann, W. Dummer, T. Wolfe, E. Rodrigo, A. N. Theofilopoulos, M. B. A. Oldstone, and M. G. von Herrath Lack of Intrinsic CTLA-4 Expression Has Minimal Effect on Regulation of Antiviral T-Cell Immunity J. Virol., January 1, 2006; 80(1): 270 - 280. [Abstract] [Full Text] [PDF] S. Mukherjee, A. Ahmed, and D. Nandi CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A J. Leukoc. Biol., July 1, 2005; 78(1): 144 - 157. [Abstract] [Full Text] [PDF] T. J. Dillon, K. D. Carey, S. A. Wetzel, D. C. Parker, and P. J. S. Stork Regulation of the Small GTPase Rap1 and Extracellular Signal-Regulated Kinases by the Costimulatory Molecule CTLA-4 Mol. Cell. Biol., May 15, 2005; 25(10): 4117 - 4128. [Abstract] [Full Text] [PDF] S. Sehra, D. Patel, S. Kusam, Z.-Y. Wang, C.-H. Chang, and A. L. Dent A Role for Caspases in Controlling IL-4 Expression in T Cells J. Immunol., March 15, 2005; 174(6): 3440 - 3446. [Abstract] [Full Text] [PDF] P. Pandiyan, D. Gartner, O. Soezeri, A. Radbruch, K. Schulze-Osthoff, and M. C. Brunner-Weinzierl CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase Function J. Exp. Med., March 15, 2004; 199(6): 831 - 842. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by da Rocha Dias, S. Articles by Rudd, C. E. Search for Related Content PubMed PubMed Citation Articles by da Rocha Dias, S.